NBIX Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Neurocrine Biosciences (NASDAQ: NBIX)
›
Neurocrine Biosciences (NASDAQ: NBIX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,500 employees.
The shares were at 156.59 USD on 19 November 2026, up 1.2% over 52 weeks. Its 52-week range is 122.14 USD to 186.12 USD: the price is 15.9% below the high and 28.2% above the low.
At a market capitalisation of 15.85B USD, it trades at 23.2 times trailing earnings and 12.7 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.3, a discount of 12% for NBIX.
Neurocrine Biosciences reports return on equity of 14.7%, an operating margin of 26.6% and revenue up 41.2% year over year.
It holds more cash than debt, a net cash position of 286.10M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 28 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 208.54 USD is 33.2% above the current price. The next earnings report is expected on 11 February 2027.